



INDIVIDUAL IDENTITY FORM
Applicant for Board membership of ABIVAX

(The following information will be provided to any shareholder who requests it, in accordance with articles R. 225-83 5° and L. 225-115 3° of the French Commercial Code (Code de commerce))

I - FULL NAME AND AGE

Troy Ignelzi

56 years old

II - PROFESSIONAL CREDENTIALS AND ACTIVITIES OVER THE PAST FIVE YEARS

Troy Ignelzi has been one of our independent directors since July 2023.

Mr. Ignelzi has served as the Chief Financial Officer of Rapport Therapeutics, Inc. since November 2023. Prior to that, Mr. Ignelzi was the Chief Financial Officer of Karuna Therapeutics, Inc. from March 2019 to October 2023, of scPharmaceuticals Inc. from March 2016 to February 2019, and provided consulting services to scPharmaceuticals Inc. in February and March 2016. Mr Ignelzi had previously held various management positions in both listed and unlisted biotech and pharmaceutical companies.

Mr. Ignelzi currently serves as a member of the board of directors of Vedanta Biosciences, Inc. and previously served as a member of the board of directors of CinCor Pharma, Inc.

Mr. Ignelzi has a B.S. in accounting from Ferris State University.

III - POSITIONS OR FUNCTIONS CURRENTLY HELD IN THE COMPANY

Board member and Chairman of the Company's Audit Committee

IV - COMPANY SHARES HELD BY THE APPLICANT

None



INDIVIDUAL IDENTITY FORM
Applicant for Board membership of ABIVAX

(The following information will be provided to any shareholder who requests it, in accordance with articles R. 225-83 5° and L. 225-115 3° of the French Commercial Code (Code de commerce))

I - FULL NAME AND AGE

June Lee

58 years old

II - PROFESSIONAL CREDENTIALS AND ACTIVITIES OVER THE PAST FIVE YEARS

June Lee has been one of our independent directors since July 2023.

Dr. Lee has served as founding CEO of Renasant Bio from January to December of 2023 and as Chairperson of the Board since December 2023. In addition, June Lee has served as a venture partner at 5AM Venture Management, LLC since July 2022. Dr. Lee was most recently Founder and Chief Executive Officer of Esker Therapeutics until September 2021. Dr. Lee previously served as the Executive Vice President and Chief Development Officer of MyoKardia, Inc. from January 2019 to June 2020, and was the Chief Operating Officer from February 2017 until January 2019, and the Chief Development Officer from October 2017 to January 2019.

From April 2011 until February 2017, Dr. Lee served on the faculty of the University of California, San Francisco, or UCSF, where she was director of the Catalyst program at the Clinical and Translational Science Institute and a professor in the School of Medicine, and was responsible for overall strategy and operations for enabling and supporting translational research at the university. Catalyst is an internal UCSF accelerator for therapeutics, devices, diagnostics, and digital health technologies.

Prior to UCSF, Dr. Lee was a disease area lead, early clinical development, at Genentech, Inc. from 2006 to 2011, where she was responsible for all strategy and activities as well as management of staff, budget, and resource allocation in the early clinical development group in multiple therapeutic areas. Dr. Lee served as a Medical Director in the clinical development group at Genentech, Inc. from 2004 to 2006, where she was responsible for clinical activities for licensed product of the company. She currently serves on Johns Hopkins University Center for Therapeutic Translation's Advisory Board, serves on the board of directors of Tenaya Therapeutics Inc, Eledon Pharmaceuticals Inc. and GenEdit, is a member of the Scientific Advisory Board for Foresite Labs, and previously served as a member of the board of directors of CinCor Pharma, Inc. Dr. Lee holds a B.A. in chemistry from Johns Hopkins University and an M.D. from the University of California, Davis.

III - POSITIONS OR FUNCTIONS CURRENTLY HELD IN THE COMPANY

Board member and chairman of the Company's Recruitment and Compensation Committee

IV - COMPANY SHARES HELD BY THE APPLICANT

None



INDIVIDUAL IDENTITY FORM
Applicant for Board membership of ABIVAX

(The following information will be provided to any shareholder who requests it, in accordance with articles R. 225-83 5° and L. 225-115 3° of the French Commercial Code (Code de commerce))

I - FULL NAME AND AGE

Camilla Soenderby

52 years old

II - PROFESSIONAL CREDENTIALS AND ACTIVITIES OVER THE PAST FIVE YEARS

Camilla Soenderby has been one of our independent directors since March 2024.

Currently, Ms. Soenderby is a member of the Board of Directors for the investment company BB Biotech and the two biotech companies, F2G and Affibody. In addition, she is a member of Novo Holdings Advisory Group and industrial advisor for the private equity group EQT. Most recently, Ms. Soenderby served as Corporate Officer, member of the Takeda Executive Team, leading global portfolio commercialisation and global commercial excellence-from 2019 to 2020. She played a critical role for the integration of Shire into Takeda, having previously served as Senior Vice President, Head of Global Product Strategy at Shire. Prior to that Ms. Soenderby was Region Head for Roche Pharma with profit and loss responsibility for 11 countries in Central, South and Eastern Europe. Prior to that, she worked as General Manager for Abbott (now AbbVie), first in Sweden and later in the United Kingdom. She also held several operational and strategic roles of increasing responsibility at Schering Plough in Asia Pacific, including General Manager for Taiwan. Ms. Soenderby began her career as a management consultant at McKinsey & Company focusing on the bio-pharmaceutical and medical device industries. Ms. Soenderby holds a MSc in Political Science from the University of Copenhagen.

III - POSITIONS OR FUNCTIONS CURRENTLY HELD IN THE COMPANY

Board member and member of the Company's Recruitment and Compensation Committee

IV - COMPANY SHARES HELD BY THE APPLICANT

None